Impact
We want to push the boundaries of science and medicine improving patient’s life
Disruptive
We look for highly innovative and transformative technologies
Hands-on
We consider ourselves partners and collaborators to our portfolio companies
Our portfolio
Accure Therapeutics
Accure Therapeutics
Agomab
Agomab
ALLOX
ALLOX
Amelia
Amelia
Anaconda
Anaconda
Augustine Therapeutics
Augustine Therapeutics
Binx Health
Binx Health
Deepull
Deepull
Gradient Denervation Technologies
Gradient Denervation Technologies
Inbiomotion
Inbiomotion
Inbrain Neuroelectronics
Inbrain Neuroelectronics
Medasense
Medasense
Mediktor
Mediktor
Nuage
Nuage
Ona Therapeutics
Ona Therapeutics
Origo Biopharma
Origo Biopharma
Oriva
Oriva
Orikine Bio
Orikine Bio
Peptomyc
Peptomyc
Qida
Qida
Quibim
Quibim
SafeHeal
SafeHeal
Sidekick
Sidekick
Splice Bio
Splice Bio
XR Health
XR Health
Our team
All Members
Josep Ll. Sanfeliu
Co-founder and managing partner
Clara Campàs
Co-founder and managing partner
Sylvain Sachot
Partner
Guillem Masferrer
Partner
Montse Vendrell
Partner
Jose María Fernández
Partner
Emilio Erazo-Fischer
Operating Partner
Núria Aloy
CFO
Maite Malet
Principal
Isabel Jimenez
Principal
Antonio Limatola
Senior Associate
Anna Bellmunt
Senior Associate
Beatriz Gandarias
Senior Associate
Joana Correia
Senior Analyst
Diana Araoz
Financial Controller
Pilar Almajano
Financial Controller
Mònica Sabé
Executive Assistant- Office Manager
Laia Romero
Executive Assistant
Responsible venture capital
Aware of the importance of taking responsibility for its potential social and environmental impacts, Asabys aligns its practices and policies with the United Nations Sustainable Development Goals (SDGs).
Asabys integrates environmental, social and governance (ESG) considerations into its investment processes, in accordance with applicable regulatory requirements.
Asabys benefits from the financial backing of the EU under the EFSI set up under the investment Plan for Europe